Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | ACP1 | P24666 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | RGS12 | O14924 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11922537 | 0.76 | ADORA2A (0.43) | FDPSSMN1; SMN2ALDH1A1PKMMEN1 | |
| SCHEMBL115952 | 0.76 | — | — | |
| SCHEMBL19736607 | 0.75 | FDPS (0.41) | FDPSSMN1; SMN2ACP1ALDH1A1PKM | |
| Hydrochloric Acid SCHEMBL5847817 | 0.74 | SMN1; SMN2 (0.41) | FDPSSMN1; SMN2EPHX2ACP1ALDH1A1 | |
| SCHEMBL12193396 | 0.73 | ADORA2A (0.39) | FDPSSMN1; SMN2ALDH1A1PKMMEN1 | |
| SCHEMBL19468539 | 0.72 | FDPS (0.58) | FDPSSMN1; SMN2ACP1ALDH1A1MEN1 | |
| SCHEMBL622574 | 0.72 | MEN1 (0.45) | FDPSSMN1; SMN2ACP1ALDH1A1PKM | |
| SCHEMBL19936029 | 0.70 | ADORA2A (0.37) | FDPSSMN1; SMN2ALDH1A1PKMMEN1 | |
| SCHEMBL6039575 | 0.69 | — | — | |
| SCHEMBL4580288 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170360811-A1 | NOVEL BISPHOSPHONIC ACID DERIVATIVE AND APPLICATION FOR SAME | NAGASAKI UNIVERSITY (JP) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360811-A1 | NOVEL BISPHOSPHONIC ACID DERIVATIVE AND APPLICATION FOR SAME | BPGM, PMM2, PGM2 | FDPS 2718/4885SMN1; SMN2 2586/4885EPHX2 2185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.